International Clinical Trial: Effectiveness of sequential use of low dose monthly emicizumab and factor concentrate prophylaxis among patient with hemophilia A without inhibitor

Geneva, Aug. 5 -- International Clinical Trials Registry received information related to the study (TCTR20250720003) titled 'Effectiveness of sequential use of low dose monthly emicizumab and factor concentrate prophylaxis among patient with hemophilia A without inhibitor' on July 20.

Study Type: Interventional

Study Design: N/A

Primary Sponsor: N/A

Condition: The non-factor therapy of emicizumab, a humanized bispecific monoclonal antibody binding factor IXa and factor X, has shown its effectiveness in preventing bleeding episodes by creating adequate factor Xa to promote clot formation. It can be applied to patients with hemophilia with and without inhibitor as prophylaxis. The subcutaneous injection of emicizumab of the loading do...